3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 3
1
Phase 2
1
Status
Recruiting
4
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
4
Sponsor
Cancer Type
Tumor-Agnostic
2
Other hematologic neoplasm
2
Lymphoid
2
Dermatologic
1
CNS
1
Conditions
Neoplasms
4
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Lymphoproliferative Disorders
2
Glioma
2
Melanoma
1
Locally Advanced Thyroid Gland Carcinoma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Interventions
pembrolizumab
38
Blood Specimen Collection
38
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
17
Exercise
17
Carboplatin
17
Nivolumab
15
atezolizumab
14
Paclitaxel
14
Cisplatin
14
Drug Therapy
13
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
11
Trastuzumab
10
Pemetrexed
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
entrectinib
×
Clear all
NCT05862285
2026-05-12
UmbrellaMAX
Hoffmann-La Roche
Phase 3
Recruiting
100 enrolled
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT02925234
2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2
Recruiting
1,550 enrolled